GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Valuation Rank

Poseida Therapeutics (STU:2RZ) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Poseida Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (STU:2RZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Valuation Rank
Comparable Companies
MACK CBUS DNTH GRTS IVVD CRMD IMRX ATXS INZY AEON OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PSTX:USA
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.poseida.com
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.